ArticleAIDS and behavior2026
Incidence and Predictors of Severe Adverse Drug Reaction Among Adult HIV Patients Initiated with Highly Active Antiretroviral Therapy in Northwest Ethiopia: A Retrospective Follow-up Study.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe adverse drug reactions (ADRs) associated with antiretroviral therapy (ART) present a major public health challenge, particularly in resource-limited settings like Ethiopia where pharmacovigilance systems are often constrained. Despite the widespread rollout of ART, contemporary evidence on the incidence and predictors of these severe events in the Ethiopian context remains limited. This study aimed to determine the time to development of severe ADRs and identify their significant predictors among adults receiving ART in Northwest Ethiopia. A retrospective follow-up study was conducted, enrolling 634 HIV-positive adults who initiated ART between April 1, 2018, and March 31, 2023. Participants were selected using a stratified random sampling technique. Data were extracted meticulously from patient medical records and analyzed using STATA version 17. Survival analysis was performed using Kaplan-Meier curves and log-rank tests, while bi-variable and multivariable Cox proportional hazards regression models were carried out to identify independent predictors. Over a total follow-up period of 16,315 person-months, 29 patients developed severe ADRs, with the majority of incidents occurring within the first 9 to 21 months of treatment initiation. The overall incidence density was calculated at 18 per 10,000 person-months (95% CI: 12, 26). Multivariable analysis identified advanced baseline WHO clinical stage (III & IV) (Adjusted Hazard Ratio [AHR] = 9.86, 95% CI: 5.21, 13.24) and a low baseline CD4 count below 350 cells/μL (AHR = 3.21, 95% CI: 1.01, 5.43) as statistically significant predictors for a shorter time to severe ADR. The findings indicate that the risk is highest in the initial months of therapy and is strongly correlated with advanced disease stage and immunosuppression at baseline. This underscores the critical need for intensified clinical monitoring and counseling for high-risk patients, especially during the first year of ART, and highlights the urgency of strengthening national pharmacovigilance systems to improve patient safety outcomes.
Indexed as
Identifiers
41369962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.